• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Regen BioPharma and NIH in Cancer Research Collaboration

Article

20 January, 2016.

Regen BioPharma (San Diego, CA) has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to jointly explore the biology of the NR2F6 protein.

The collaboration will focus on identifying ligands for the nuclear receptor NR2F6, which has been identified as a potentially important immune cell inhibitor and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists and antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system.

Related Videos
Related Content
Abid Rahman

Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA

April 19th 2024
Article

Rahman discusses the new opportunities that digital twins present to researchers.

UniDoc

UniDoc Brings AI-Powered Health Cube to Alaska

April 17th 2024
Article

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Riccardo Butta

At-Home Patients and AI: Q&A with Riccardo Butta

April 16th 2024
Article

Butta discusses how new technologies are being implemented in at-home devices.

Say Hello to Flexible: Reimagining the Patient Journey

Say Hello to Flexible: Reimagining the Patient Journey

April 15th 2024
Article

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Stock.adobe.com

ArisGlobal Announces Second Life Sciences Generative AI Council Session

April 11th 2024
Article

The meeting is scheduled for May in Switzerland.

Image credit: ArtemisDiana | stock.adobe.com

Precision Medicine: Investments and Outcomes Expected

March 18th 2024
Article

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.